Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Development and Standardization of an Improved Type 1 Diabetes Genetic Risk Score for Use in Newborn Screening and Incident Diagnosis.

Sharp SA, Rich SS, Wood AR, Jones SE, Beaumont RN, Harrison JW, Schneider DA, Locke JM, Tyrrell J, Weedon MN, Hagopian WA, Oram RA.

Diabetes Care. 2019 Feb;42(2):200-207. doi: 10.2337/dc18-1785.

PMID:
30655379
2.

The Common HNF1A Variant I27L Is a Modifier of Age at Diabetes Diagnosis in Individuals With HNF1A-MODY.

Locke JM, Saint-Martin C, Laver TW, Patel KA, Wood AR, Sharp SA, Ellard S, Bellanné-Chantelot C, Hattersley AT, Harries LW, Weedon MN.

Diabetes. 2018 Sep;67(9):1903-1907. doi: 10.2337/db18-0133. Epub 2018 Jun 12.

3.

N-alkylated isatins evade P-gp mediated efflux and retain potency in MDR cancer cell lines.

Vine KL, Belfiore L, Jones L, Locke JM, Wade S, Minaei E, Ranson M.

Heliyon. 2016 Jan 21;2(1):e00060. doi: 10.1016/j.heliyon.2015.e00060. eCollection 2016 Jan.

4.

Functional characterisation of ADIPOQ variants using individuals recruited by genotype.

Lee BP, Lloyd-Laney HO, Locke JM, McCulloch LJ, Knight B, Yaghootkar H, Cory G, Kos K, Frayling TM, Harries LW.

Mol Cell Endocrinol. 2016 Jun 15;428:49-57. doi: 10.1016/j.mce.2016.03.020. Epub 2016 Mar 17.

PMID:
26996131
5.

Role of microRNAs in the age-associated decline of pancreatic beta cell function in rat islets.

Tugay K, Guay C, Marques AC, Allagnat F, Locke JM, Harries LW, Rutter GA, Regazzi R.

Diabetologia. 2016 Jan;59(1):161-169. doi: 10.1007/s00125-015-3783-5.

6.

A cautionary tale: the non-causal association between type 2 diabetes risk SNP, rs7756992, and levels of non-coding RNA, CDKAL1-v1.

Locke JM, Wei FY, Tomizawa K, Weedon MN, Harries LW.

Diabetologia. 2015 Apr;58(4):745-8. doi: 10.1007/s00125-015-3508-9. Epub 2015 Jan 30.

7.

Targeted allelic expression profiling in human islets identifies cis-regulatory effects for multiple variants identified by type 2 diabetes genome-wide association studies.

Locke JM, Hysenaj G, Wood AR, Weedon MN, Harries LW.

Diabetes. 2015 Apr;64(4):1484-91. doi: 10.2337/db14-0957. Epub 2014 Nov 12.

8.

Increased expression of miR-187 in human islets from individuals with type 2 diabetes is associated with reduced glucose-stimulated insulin secretion.

Locke JM, da Silva Xavier G, Dawe HR, Rutter GA, Harries LW.

Diabetologia. 2014 Jan;57(1):122-8. doi: 10.1007/s00125-013-3089-4. Epub 2013 Oct 23.

9.

The splice site variant rs11078928 may be associated with a genotype-dependent alteration in expression of GSDMB transcripts.

Morrison FS, Locke JM, Wood AR, Tuke M, Pasko D, Murray A, Frayling T, Harries LW.

BMC Genomics. 2013 Sep 17;14:627. doi: 10.1186/1471-2164-14-627.

10.

A rare SNP in pre-miR-34a is associated with increased levels of miR-34a in pancreatic beta cells.

Locke JM, Lango Allen H, Harries LW.

Acta Diabetol. 2014 Apr;51(2):325-9. doi: 10.1007/s00592-013-0499-1. Epub 2013 Jul 5.

11.

The antiangiogenic properties of sulfated β-cyclodextrins in anticancer formulations incorporating 5-fluorouracil.

Watson CA, Vine KL, Locke JM, Bezos A, Parish CR, Ranson M.

Anticancer Drugs. 2013 Aug;24(7):704-14. doi: 10.1097/CAD.0b013e3283626fdd.

PMID:
23695012
12.

MicroRNA expression profiling of human islets from individuals with and without type 2 diabetes: promises and pitfalls.

Locke JM, Harries LW.

Biochem Soc Trans. 2012 Aug;40(4):800-3. doi: 10.1042/BST20120049. Review.

PMID:
22817737
13.

Anti-cancer activity of an acid-labile N-alkylisatin conjugate targeting the transferrin receptor.

Indira Chandran V, Matesic L, Locke JM, Skropeta D, Ranson M, Vine KL.

Cancer Lett. 2012 Mar 28;316(2):151-6. doi: 10.1016/j.canlet.2011.10.021. Epub 2011 Nov 22.

PMID:
22115965
14.

Targeting urokinase and the transferrin receptor with novel, anti-mitotic N-alkylisatin cytotoxin conjugates causes selective cancer cell death and reduces tumor growth.

Vine KL, Indira Chandran V, Locke JM, Matesic L, Lee J, Skropeta D, Bremner JB, Ranson M.

Curr Cancer Drug Targets. 2012 Jan;12(1):64-73.

PMID:
22111834
15.

An alternative polyadenylation signal in TCF7L2 generates isoforms that inhibit T cell factor/lymphoid-enhancer factor (TCF/LEF)-dependent target genes.

Locke JM, Da Silva Xavier G, Rutter GA, Harries LW.

Diabetologia. 2011 Dec;54(12):3078-82. doi: 10.1007/s00125-011-2290-6. Epub 2011 Sep 14. Erratum in: Diabetologia. 2011 Dec;54(12):3170.

16.

Synthesis and hydrolytic evaluation of acid-labile imine-linked cytotoxic isatin model systems.

Matesic L, Locke JM, Vine KL, Ranson M, Bremner JB, Skropeta D.

Bioorg Med Chem. 2011 Mar 1;19(5):1771-8. doi: 10.1016/j.bmc.2011.01.015. Epub 2011 Jan 14.

PMID:
21306903
17.

Genome-wide homozygosity analysis reveals HADH mutations as a common cause of diazoxide-responsive hyperinsulinemic-hypoglycemia in consanguineous pedigrees.

Flanagan SE, Patch AM, Locke JM, Akcay T, Simsek E, Alaei M, Yekta Z, Desai M, Kapoor RR, Hussain K, Ellard S.

J Clin Endocrinol Metab. 2011 Mar;96(3):E498-502. doi: 10.1210/jc.2010-1906. Epub 2011 Jan 20.

18.

Preclinical evaluation of novel, all-in-one formulations of 5-fluorouracil and folinic acid with reduced toxicity profiles.

Stutchbury TK, Vine KL, Locke JM, Chrisp JS, Bremner JB, Clingan PR, Ranson M.

Anticancer Drugs. 2011 Jan;22(1):24-34. doi: 10.1097/CAD.0b013e32833f6d22.

PMID:
20881836
19.

Selective targeting of 2'-deoxy-5-fluorouridine to urokinase positive malignant cells in vitro.

Vine KL, Locke JM, Bremner JB, Pyne SG, Ranson M.

Bioorg Med Chem Lett. 2010 May 1;20(9):2908-11. doi: 10.1016/j.bmcl.2010.03.029. Epub 2010 Mar 9.

PMID:
20363130
20.

Recessive mutations in the INS gene result in neonatal diabetes through reduced insulin biosynthesis.

Garin I, Edghill EL, Akerman I, Rubio-Cabezas O, Rica I, Locke JM, Maestro MA, Alshaikh A, Bundak R, del Castillo G, Deeb A, Deiss D, Fernandez JM, Godbole K, Hussain K, O'Connell M, Klupa T, Kolouskova S, Mohsin F, Perlman K, Sumnik Z, Rial JM, Ugarte E, Vasanthi T; Neonatal Diabetes International Group, Johnstone K, Flanagan SE, Martínez R, Castaño C, Patch AM, Fernández-Rebollo E, Raile K, Morgan N, Harries LW, Castaño L, Ellard S, Ferrer J, Perez de Nanclares G, Hattersley AT.

Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3105-10. doi: 10.1073/pnas.0910533107. Epub 2010 Jan 28.

21.

Variants in the isoform-specific coding regions of the HNF1A, HNF4A and HNF1B genes are not a common cause of familial, young-onset diabetes or renal cysts and diabetes (RCAD).

Locke JM, Ellard S, Norwood VF, Harries LW.

Diabet Med. 2009 May;26(5):569-70. doi: 10.1111/j.1464-5491.2009.02705.x. No abstract available.

PMID:
19646202
22.

Development and assessment of novel all-in-one parenteral formulations with integrated anticoagulant properties for the concomitant delivery of 5-fluorouracil and calcium folinate.

Locke JM, Stutchbury TK, Vine KL, Gamble AB, Clingan PR, Bremner JB, Ranson M.

Anticancer Drugs. 2009 Oct;20(9):822-31. doi: 10.1097/CAD.0b013e32832fd78e.

PMID:
19606016
23.

Cytotoxic and anticancer activities of isatin and its derivatives: a comprehensive review from 2000-2008.

Vine KL, Matesic L, Locke JM, Ranson M, Skropeta D.

Anticancer Agents Med Chem. 2009 May;9(4):397-414. Review.

PMID:
19442041
24.

The diabetic phenotype in HNF4A mutation carriers is moderated by the expression of HNF4A isoforms from the P1 promoter during fetal development.

Harries LW, Locke JM, Shields B, Hanley NA, Hanley KP, Steele A, Njølstad PR, Ellard S, Hattersley AT.

Diabetes. 2008 Jun;57(6):1745-52. doi: 10.2337/db07-1742. Epub 2008 Mar 20.

25.

N-phenethyl and N-naphthylmethyl isatins and analogues as in vitro cytotoxic agents.

Matesic L, Locke JM, Bremner JB, Pyne SG, Skropeta D, Ranson M, Vine KL.

Bioorg Med Chem. 2008 Mar 15;16(6):3118-24. doi: 10.1016/j.bmc.2007.12.026. Epub 2008 Jan 7.

PMID:
18182300
26.

RNA processing and mRNA surveillance in monogenic diabetes.

Locke JM, Harries LW.

Gene Regul Syst Bio. 2008 May 21;2:203-12.

27.

An investigation into the cytotoxicity and mode of action of some novel N-alkyl-substituted isatins.

Vine KL, Locke JM, Ranson M, Pyne SG, Bremner JB.

J Med Chem. 2007 Oct 18;50(21):5109-17. Epub 2007 Sep 21.

PMID:
17887662
28.

Probing molecular shape. 1. Conformational studies of 5-hydroxyhexahydropyrimidine and related compounds.

Locke JM, Crumbie RL, Griffith R, Bailey TD, Boyd S, Roberts JD.

J Org Chem. 2007 May 25;72(11):4156-62. Epub 2007 Apr 17.

PMID:
17439182
29.

In vitro cytotoxicity evaluation of some substituted isatin derivatives.

Vine KL, Locke JM, Ranson M, Benkendorff K, Pyne SG, Bremner JB.

Bioorg Med Chem. 2007 Jan 15;15(2):931-8. Epub 2006 Oct 20. Erratum in: Bioorg Med Chem. 2007 Jun 1;15(11):3951. Benkendorff, Kirsten [added].

PMID:
17088067
30.
31.

Certain factors affecting the infrared spectra of selected microorganisms.

HAYNES WC, MELVIN EH, LOCKE JM, GLASS CA, SENTI FR.

Appl Microbiol. 1958 Sep;6(5):298-304. No abstract available.

32.

Pseudomonas aureofaciens Kluyver and phenazine alpha-carboxylic acid, its characteristic pigment.

CONWAY HF, HAYNES WC, JACKSON RW, LOCKE JM, PRIDHAM TG, SOHNS VE, STODOLA FH.

J Bacteriol. 1956 Sep;72(3):412-7. No abstract available.

Supplemental Content

Loading ...
Support Center